J. Lee

发表

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma.

J. Heo, T. Sohn, C. Park, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

719PTUMOUR SHRINKAGE AT 6 WEEKS PREDICTS FAVORABLE CLINICAL OUTCOMES IN A PHASE III STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB FOR ADVANCED BILIARY TRACT CANCER.

W. Kang, H. Kim, H. Lim, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

A. Bass, W. Park, T. Sohn, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC).

I. Hwang, S. Oh, W. Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Node-positive bladder cancer after neoadjuvant chemotherapy followed by radical cystectomy: A single-center retrospective study.

J. Cho, S. Park, J. Lee, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP).

A. Eisbruch, T. Carey, C. Bradford, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

Kwhanmien Kim, H. Kim, J. Y. Choi, 2013, British Journal of Cancer.

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer

P. Tan, A. Qamra, W. Kang, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer

S. Lee, W. Kang, K. Kim, 2005, British Journal of Cancer.

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

A. Drilon, F. Nicolantonio, A. Bardelli, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer

Sin-Ho Jung, I. Hwang, S. Lim, 2015, British Journal of Cancer.

IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas

S. H. Lee, C. Jung, W. Kang, 2005, Leukemia & lymphoma.

Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)

D. Cameron, A. Wardley, R. Coleman, 2007 .

Phase II trial of carboplatin in the management of malignant mesothelioma.

P. Bye, B. McCaughan, D. Raghavan, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Innovative personalized medicine in gastric cancer: time to move forward

S. Ou, S. Ou, W. Kang, 2014, Clinical genetics.

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD1 therapy.

W. Park, J. Armenia, M. Kwon, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

S H Lee, W. Park, Jeeyun Lee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma

D. Yu, J. Myers, T. Jiffar, 2011, Oncogene.

Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.

K. Jang, M. Kwon, S. Byeon, 2020, ESMO open.

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

D. Yim, H. Lim, J. Park, 2012, British Journal of Cancer.

MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines

W. Kang, H. Lim, S. Park, 2017, Journal of Cancer.

PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer

J. Barrett, S. Park, D. Hodgson, 2018, Oncoimmunology.

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.

J. Y. Lee, D. Na, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.

H. Lim, J.O. Park, J. Lee, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

A High Thymidylate Synthase Expression is Related to Better Outcome for Advanced Gastric Cancer Patients Treated with 5-FU Chemotherapy after Curative Resection

M. Cho, Hwan Kim, M. Eom, 2006 .

Significance of pretreatment hemoglobin level in patients with T1 glottic cancer.

D. Schultz, W. Regine, M. Mohiuddin, 1999, Radiation oncology investigations.

722PMOLECULAR SUBGROUP ANALYSIS OF CLINICAL OUTCOMES IN A PHASE 3 STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB IN ADVANCED BILIARY TRACT CANCER.

W. Kang, H. Kim, Ho Yeong Lim, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.

W. Kang, H. J. Kim, H. Lim, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

1339PDPHASE II TRIAL OF EPIDERMAL GROWTH FACTOR OINTMENT FOR PATIENTS WITH ERLOTINIB-RELATED SKIN EFFECTS.

I. Hwang, H. Kim, C. Son, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.

S. Yoon, H. Lim, J. Park, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.

D. Doval, S. Thongprasert, J. Yi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC).

M. Millenson, H. Borghaei, C. Langer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis.

D. Lim, T. Sohn, J. Bae, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

One cycle of induction chemotherapy (IC) in advanced oropharyngeal cancer (SCCOP) to select patients for organ preservation (OP)

C. Tsien, A. Eisbruch, T. Carey, 2005 .

Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma.

H. Jang, D. Shin, H. Jeung, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

722PMOLECULAR SUBGROUP ANALYSIS OF CLINICAL OUTCOMES IN A PHASE 3 STUDY OF GEMCITABINE AND OXALIPLATIN WITH OR WITHOUT ERLOTINIB IN ADVANCED BILIARY TRACT CANCER.

H. Kim, Ho Yeong Lim, W. Kang, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: Preliminary results.

M. Grever, J. Byrd, R. Baiocchi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.